BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sacco F, Spezzaferro M, Amitrano M, Grossi L, Manzoli L, Marzio L. Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment. Digestive and Liver Disease 2010;42:110-4. [DOI: 10.1016/j.dld.2009.05.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Pranger AD, Kosterink JG, van Altena R, Aarnoutse RE, van der Werf TS, Uges DR, Alffenaar JC. Limited-Sampling Strategies for Therapeutic Drug Monitoring of Moxifloxacin in Patients With Tuberculosis. Therapeutic Drug Monitoring 2011;33:350-4. [DOI: 10.1097/ftd.0b013e31821b793c] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
2 Ladrón-de-Guevara L, Bornstein-Quevedo L, González-Huezo S, Castañeda-Romero B, Costa FG, di Silvio-López M. Helicobacter pylori eradication in Mexico with a levofloxacin-based scheme versus standard triple therapy: Results from an open-label, randomized, noninferiority phase iiib trial. Rev Gastroenterol Mex (Engl Ed) 2019;84:274-83. [PMID: 30060902 DOI: 10.1016/j.rgmx.2018.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
3 Ciccaglione AF, Cellini L, Grossi L, Marzio L. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pyloriWorld J Gastroenterol 2012; 18(32): 4386-4390 [PMID: 22969203 DOI: 10.3748/wjg.v18.i32.4386] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
4 Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori: . Current Opinion in Gastroenterology 2011;27:565-70. [DOI: 10.1097/mog.0b013e32834bb818] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
5 Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, Madisch A, Laass MW, Neumeyer M, Jebens C, Zekorn C, Knoth H, Vieth M, Stolte M, Lehn N, Morgner A. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter. 2011;16:420-426. [PMID: 22059392 DOI: 10.1111/j.1523-5378.2011.00867.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
6 Xirouchakis E, Georgopoulos SD. Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review. Expert Opin Pharmacother 2021;:1-10. [PMID: 34595999 DOI: 10.1080/14656566.2021.1982894] [Reference Citation Analysis]
7 Pan XX, Sun L. Clinical effects of esomeprazole, amoxicillin and clarithromycin combined with traditional Chinese medicine decoction in treatment of peptic ulcer bleeding. Shijie Huaren Xiaohua Zazhi 2014; 22(27): 4181-4185 [DOI: 10.11569/wcjd.v22.i27.4181] [Reference Citation Analysis]
8 Sierra F, Forero JD, Rey M. [Ideal treatment for Helicobacter pylori: a systematic review]. Rev Gastroenterol Mex 2014;79:28-49. [PMID: 24365458 DOI: 10.1016/j.rgmx.2013.03.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
9 Ergül B, Koçak E, Taş A, Filik L, Köklü S. Bismuth, moxifloxacin, tetracycline, lansoprazole quadruple first line therapy for eradication of H. pylori: A prospective study. Clin Res Hepatol Gastroenterol 2013;37:527-9. [PMID: 23312494 DOI: 10.1016/j.clinre.2012.10.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
10 Berning M, Krasz S, Miehlke S. Should quinolones come first in Helicobacter pylori therapy? Therap Adv Gastroenterol. 2011;4:103-114. [PMID: 21694812 DOI: 10.1177/1756283x10384171] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
11 Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:209-221. [PMID: 22129228 DOI: 10.1111/j.1365-2036.2011.04937.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 113] [Article Influence: 10.5] [Reference Citation Analysis]
12 Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017;8:123-30. [DOI: 10.1016/j.jgar.2016.11.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
13 Gisbert JP. Rifabutin for the Treatment of Helicobacter Pylori Infection: A Review. Pathogens 2020;10:15. [PMID: 33379336 DOI: 10.3390/pathogens10010015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 Gisbert JP. Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules 2020;25:E5084. [PMID: 33147814 DOI: 10.3390/molecules25215084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, Borm G, Aarnoutse RE, van Crevel R. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. The Lancet Infectious Diseases 2013;13:27-35. [DOI: 10.1016/s1473-3099(12)70264-5] [Cited by in Crossref: 203] [Cited by in F6Publishing: 87] [Article Influence: 22.6] [Reference Citation Analysis]
16 Gisbert JP, Romano M, Molina-Infante J, Lucendo AJ, Medina E, Modolell I, Rodríguez-Tellez M, Gomez B, Barrio J, Perona M. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. Dig Liver Dis. 2015;47:108-113. [PMID: 25454706 DOI: 10.1016/j.dld.2014.10.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
17 Selgrad M, Bornschein J, Malfertheiner P. Guidelines for treatment of Helicobacter pylori in the East and West. Expert Rev Anti Infect Ther. 2011;9:581-588. [PMID: 21819326 DOI: 10.1586/eri.11.80] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
18 Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;CD008337. [PMID: 24338763 DOI: 10.1002/14651858.cd008337.pub2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 54] [Article Influence: 3.1] [Reference Citation Analysis]
19 Chotivitayatarakorn P, Mahachai V, Vilaichone RK. Effectiveness of 7-Day and 14-Day Moxifloxacin-Dexlansoprazole Based Triple Therapy and Probiotic Supplement for Helicobacter Pylori Eradication in Thai Patients with Non-Ulcer Dyspepsia: A Double-Blind Randomized Placebo-Controlled Study. Asian Pac J Cancer Prev 2017;18:2839-43. [PMID: 29072432 DOI: 10.22034/APJCP.2017.18.10.2839] [Reference Citation Analysis]